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The photodynamic therapy (PDT) is an alternative technique that can be used for treating
superficial basal cell carcinoma (sBCC), Bowen’s disease and actinic keratosis with
highefficiency. The objective of this study is to present a method where fluorescence
imaging together with for PDT as a monitoring guidance in real time. Confirming that
the lesion is well prepared and the photosensitizer shows a homogenous distribution,
the outcome after few PDT sessions will be more predictable and the recurrence is
minimized. Our proposition in this study is use the widefield fluorescence imaging to
evaluate the PDT protocol in situ and in real time for each lesion. This evaluation
procedure is performed in two steps: first with the monitoring of the production
of protoporphyrin IX (PpIX) induced by methyl aminolevulinate (MAL), a derivative of
5-aminolevulinic acid (ALA) and second with the detection of PpIX photobleaching
after illumination. The fluorescence images provide information correlated with distinct
clinical features and with the treatment outcome. Eight BCC lesions are presented
and discussed in this study. Different fluorescence patterns of PpIX production and
photobleaching could be correlated with the treatment response. The presented results
show the potential of using widefield fluorescence imaging as a guidance tool to
customized PDT. This procedure is being incorporated to the main PDT skin cancer
protocol applied in Brazil with an excellent outcome.
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Introduction
Photodynamic therapy (PDT) is a treatment modality that can be used for several cancer types and
pre-cancer lesions, like superficial basal cell carcinoma (sBCC), Bowen’s disease and actinic kerato-
sis. The PDT is based on the combination of a photosensitizer (PS), the molecular oxygen within
the cells and a suitable light source. The photosensitizer is a molecule, which absorbs light at specific
wavelengths, and once the light is absorbed, the molecule passes from the ground state to an excited
state. From this excited metastable state, the molecule can transfer energy to other molecules, start-
ing the photodynamic reaction, or the molecule returns to the ground state releasing energy as
photons, a irradiative process known as fluorescence [1–7], which identifies the presence of the
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photo sensible molecules. While the photodynamic route takes
to the killing of cell, the fluorescence is on mechanism for
diagnostic.
The fluorescence properties of most PSs can be used for pho-
todynamic diagnosis. This type of clinical application has been
widely reported in literature [8–10]. This is possible because
the photosensitizer molecules have higher affinity to cancer cells
compared to normal cells. It has been shown widely in preclini-
cal and clinical studies that PS fluorescence can be useful contrast
for improved visualization of cancer region and help surgeons
delineating tumor margins during surgical resections [11–13].By
using 5-aminolevulinic acid (ALA) or the methyl aminolevuli-
nate (MAL) as precursor of protoporphyrin IX (PpIX), it is pos-
sible to use fluorescence to quantify PpIX content at pre- and
post-treatment [6, 14–16].
It has been shown that singlet oxygen is generated and PS
is being consumed continuously during PDT (as called photo-
bleaching process) and this consumption can be related to PDT
outcome [13, 17, 18].Thus, one can get information about the
PDT efficacy by quantifying the PpIX content before and after
PDT. The observation of the accumulated PpIX fluorescence is
crucial in quantifying photosensitizer content before PDT. On
the other hand if fluorescence signal is decreased significantly
after PDT, one can infer that a significant amount of photoreac-
tion has occurred and substantial level of singlet oxygen has been
generated due to PDT [3, 19, 20]. Thus, if one measures PpIX flu-
orescence after PDT, the fluorescence level can indicate that the
photosensitizer was consumed and there is a good level of pho-
todynamic reaction. On the other hand, if the PpIX fluorescence
is high after PDT, it may imply an insufficient level of photore-
action and a lack of singlet oxygen generation. This fluorescence
monitoring has practical benefits for optimizing the treatment at
the clinical settings.
Based on previous studies [13, 15, 21], the aim of this work
is to implement fluorescence imaging in a clinical protocol to
improve the clinical outcome. In our multi-center clinical trial of
PDT for skin cancer in Brazil, we have added three fluorescence
measurements during PDT implementation. First we measured
before the application of the photosensitizer PpIX. In this case the
fluorescence originated from tissue itself, as called auto fluores-
cence. Second time point was 3 h after application of the cream,
so that fluorescence provided accumulated PpIX content in the
lesion. And finally, we measured at the end of the PDT treatment
to assess the PpIX photobleaching due to PDT.
The manuscript structure is as follows: In the next sec-
tion we introduce the materials and methods where we
describe the details related to chemicals, patient and instru-




The pro-drug used was the commercial methyl aminolevulinate
(MAL) obtained from PDT-PHARMA (Cravinhos, São Paulo -
Brazil) in 20% concentrations in oil and water emulsion (O/W).
Patients
This study is a part of a Brazilian program for the treatment
of skin cancer using PDT [22]. The patients were treated at
the Amaral Carvalho Hospital (Jaú, SP, Brazil). The fluorescence
monitoring of the PS was performed in seven different patients,
ranging from 59 to 77 years old, presenting different skin pho-
totypes (I-IV) and lesions in different anatomical sites. The PDT
protocol was approved by Ethics Committee of Fundação Hospi-
tal Amaral Carvalho (73th Ethical Committee Meeting on Octo-
ber 28, 2011), and the patients signed an informed consent form
before being enrolled in the clinical study. The response to the
treatment, classified as complete or partial response, was assessed
through histopathology 30 days after the second session of PDT
and follow-up of after 6 months.
Lesion Identification
The BCC lesions were identified by clinical evaluation and classi-
fied as nodular, superficial and pigmented. The hypothesis confir-
mation of clinical evaluation was performed by histopathological
diagnosis, conducted by the pathology service of Amaral Car-
valho Hospital, confirming the presence or absence of sBCC. The
criterion of exclusion was the use of only superficial lesions.
Lesion Preparation
Lesions were previously cleaned with chlorhexidine solution and
curetted for removal of the skin horny layer. This procedure facil-
itates the transdermal delivery of the MAL cream and optimizes
the light coupling in the tissue. The 20%MAL cream was applied
on the lesion with a layer about 3mm thick and 2mm beyond
the clinical lesion edges. Then the lesions were covered with an
occlusive curative using plastic film, aluminum foil and bandage
to prevent light exposure. The drug-light interval was 3 h.
Fluorescence Images
The fluorescence images were acquired 3 h after 20%MAL cream
application before the first and second PDT session and imme-
diately after the PDT procedure in the first and in the second
session (after 7 days). A PDT device (Lince, MMOptics, São Car-
los, SP- Brazil) was developed presenting a dual platform: a wide-
field fluorescence imaging system that is based on 405 nm LED
(Light Emitting Diode) arrays that allow observing the fluores-
cence emission over 450 nm and an illumination probe for PDT
treatment constituted with 630 nm LED (Light Emitting Diodes)
arrays (Figure 1). Having both functions at the same device (opti-
cal diagnosis and PDT treatment light illumination) has made
the use of fluorescence guided PDT a simple and more clinically
feasible procedure.
Lesions Treatment Illumination
After 3 h of cream application, the illumination procedure was
performed with an irradiance of 125mW/cm2 for about 20min,
resulting in a delivered fluence of about 150 J/cm2. A second PDT
session was performed after 7 days, following the same protocol.
This light dose was adapted based on fluorescence observations.
Image Processing and Data Analysis
Fluorescence images were analyzed with software aimed for
numerical calculation (Matlab, Matrix Laboratory, R2014a
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FIGURE 1 | Illumination system and optical diagnosis (Lince) to
photodynamic therapy procedure.
version). A routine was created to calculate the average of PpIX
fluorescence intensity in each image. The routine read the image
and the RGB channels were spitted in order to evaluate only the
red (R) channel, corresponding to the PpIX fluorescence. The
average value of fluorescence intensity was calculated for each
image, and then normalized by maximum pixel intensity (255),
which is the maximum value that a pixel in the image may have,
resulting in values from 0 to 1. More details about the wide-field
fluorescence imaging analyses can be found in our previously
papers described by Menezes et al. [23].
The widefield fluorescence imaging of PpIX production and
photodegradation, and the average of red fluorescence were com-
pared for different situations: concerning the PDT session num-
ber, the anatomical site of the lesion and the tissue response to the
therapy.
The comparisons were done before and after illumination
in the first and in the second session to evaluate the quan-
titative differences between the images, which gave informa-
tion about the formation and degradation or consumption
of PpIX.
Evaluation and Treatment Progress
The patients were evaluated in a follow-up exam after 30 days
of the second session. Clinical and histopathological analysis
was done after a punch biopsy according to complete response
(cure) or partial response (not cure). A clinical evaluation was
performed after 6 months.
Statistical Analysis
We used theMann-WhitneyU-test, a nonparametric test applied
for two independent samples, with the groups: PpIX photo-
bleaching of the first and second PDT session; PpIX formation
in two anatomical regions.
FIGURE 2 | PpIX fluorescence images of BCC lesions after 3 h of MAL
topical application (A,C,E) and after the first PDT session (B,D,F).
Results
PDT Session Number
The effect of the one-and two-session PDT was studied in PpIX
fluorescence. Figures 2, 3 display the fluorescence intensity of
three BCC lesions of three patients undergoing first and sec-
ond PDT session, respectively. The PpIX formation was higher
in the second session (Figures 3A,C,E) than in the first ses-
sion (Figures 2A,C,E). The corresponding values of PpIX pro-
duction and photodegradation are presented in Figure 4. The
three patients (Figures 2, 3—P1, P2, and P3) showed complete
response to PDT confirmed by histopathology 30 days after
second PDT session.
The results show that fluorescence related to PpIX production
in the second session was higher than in the first session for all
patients, and photodegradation was more pronounced in the first
session than in the second session (P < 0.001, two-tailed test).
Lesion Anatomical Site Influence on PpIX
Production
The PDT was performed in two lesions of different anatom-
ical sites of the same patient. Figure 5 indicate sit is possible
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FIGURE 3 | PpIX fluorescence images of BCC lesions before 3h of MAL
topical application (A,C,E) and after the second PDT session (B,D,F).
to observe the influence of anatomical body regions in the
formation of PpIX during the PDT. The anatomical regions
of BCC were near upper lip (Figures 5A,C) and eye regions
(Figures 5B,D). Variations between PpIX accumulations in
different anatomical regions were observed. The averages of red
pixels values are presented in Figure 6. The PpIX fluorescence
was higher in the lip region (Figure 6—L1) than in the eyelid
region (Figure 6—L2) (P < 0.01, two-tailed test).
Influences of PpIX Intensity on BCC Lesion
Response
The negative response to the PDT treatment by BCC lesions
showed a direct relation with the PpIX formation. The three BCC
lesions that did not present complete response to PDT are shown
in Figures 7, 8. The averages of PpIX formation calculated for
each lesion of three patients (P1, P2, and P3) is presented in
Figure 9. The results were significant (p = 0.0153).
Discussion
Photodynamic diagnosis has been widely used for cancer detec-
tion, mainly skin cancer, since photosensitizers can be used
FIGURE 4 | Mean value of red pixels in fluorescence images of different
patients (P1, P2, and P3), comparing the formation and degradation in
the first and second PDT sessions.
FIGURE 5 | PpIX fluorescence images for comparison of PPIX
formation (A,C—before PDT) and degradation (B,D—after PDT) in
different lesions of the same patient in second session of PDT.
as contrast agent for fluorescence imaging in the visible spec-
tral region improving the cancer/normal tissue discrimination
[24]. The metabolic activity and the structural and biochemical
changes of the skin cancer influences its autofluorescence [17].
Also, the production of PpIX is increased at malignant cells, so
it can work as a cancer marker. The photodynamic diagnosis is
not only used to detect cancerous tissue but also bacteria, which
when synthesizing porphyrin, the biofilm shows an intense red
autofluorescence in tooth surfaces [18]. ALA-PpIX derivative is
one of the most used markers for this purpose.
In this paper the correlation between the production and
photodegradation of PpIX during PDT and its clinical response
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FIGURE 6 | Mean value of red pixels in fluorescence images of different
lesions (L1 and L2), comparing the formation and degradation of PPIX
in different anatomical sites in the same patient.
were assessed. Factors like, PDT session number, lesion site and
intrinsic characteristics of the lesion are correlated with PpIX
fluorescence. All fluorescence images of PpIX production and
photodegradation were performed 3 h after 20% MAL topical
administration.
As expected, there was a substantial image contrast between
normal and abnormal tissues. The normal tissue shows an intense
green autofluorescence, mostly related to collagen under the
common blue excitation wavelength (e.g., 405 nm). BCC lesions
exhibit decreased autofluorescence due to the chronic inflam-
mation, resulting in a higher absorption by higher hemoglobin
content, as well as the decreased collagen emission associated
to the breakdown of the crosslinks between its fibers [1]. PpIX
ALA derivative accumulates preferentially in abnormal cells.
The increase of PpIX formation in the lesions was observed
in this study. This can be explained by the increased uptake
of MAL by the abnormal tissue. This occurs due to the cell
changes in BCC as suggested by Martin et al. [13]. Differ-
ences in the PpIX intensity may also be due to cell type from
different tissues as observed by Inada et al. [25]. PpIX pro-
duction did not differ significantly between different lesions of
the same tissue of BCC, squamous cell carcinoma (SCC) and
psoriasis [26].
The PpIX excited by blue light emits an intense red fluo-
rescence and thus PpIX fluorescence can be used as a contrast
for tumor demarcation and PDT therapy response assessment.
Therefore, this study demonstrates the effectiveness of this tool
in assessing the success of treatment. The total amount of PpIX
in tumor and its distribution in tissue determines the type of PDT
response rate. On the other hand, PpIX photobleaching is depen-
dent on the illuminations parameters [27]. The enzymatic levels
involved in the metabolism of porphyrin expression are altered
during PDT [28].
Human and animals studies showed a maximum PpIX pro-
duction 3 h after ALA or MAL cream application at skin. Since
the elimination of PpIX from skin is quite completed within 24 h,
FIGURE 7 | PpIX fluorescence images of BCC lesions after 3 h of MAL
topical application (A,C,E) and after the first PDT session (B,D,F).
performing topical PDT using these ALA and MAL pro drugs
is very advantageous compared to hematoporphyrin derivatives
that causes prolonged skin photosensitivity for 1–2 months.
The diffuse fluorescence in the areas surrounding to tumor
is explained by curettage carried out before application of the
cream. Reactive oxygen species formed by PDT cause irreversible
cellular damage. Necrotic tissue is removed in second session
of PDT, improving the cream and light penetration. However,
the PpIX formation in the second session is greater when com-
pared to the first session of PDT. This may be explained by the
alteration of metabolism during the inflammatory process. The
inflammatory process can change the cellular metabolism during
an acute response and the cellular metabolism of porphyrin in
the inflammatory process can change the accumulation of PpIX
in epithelial tissue. We also note that a lack of improved speci-
ficity for photodynamic detection of malignant tissue was also
observed at the second session.
The anatomical site influence on PDT efficacy was also mon-
itored by PpIX fluorescence. The treated lesions showed some
changes in response to treatment. The red pixel values showed
that the photodegradation of PpIX in the eyelid was approxi-
mately 37% lower than that in the upper lip region. The eye
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FIGURE 8 | PpIX fluorescence images of BCC lesions before 3h of MAL
topical application (A,C,E) and after the second PDT session (B,D,F).
lesions were in anatomical regions with irregular surfaces, result-
ing in limitation on the optimal, uniform illumination of the
whole lesion. These areas might have received a lower light
dose than the desired dose. A real-time and noninvasive way to
evaluate this type of sub dose treatment is highly attractive, since
it allows the clinician to correct the illumination planning at the
same session, after the evaluation of the PpIX photodegradation.
FIGURE 9 | Mean value of red pixels in fluorescence images of different
patients (P1, P2, and P3), comparing the formation and degradation in
the first and second PDT sessions.
Conclusion
In this study we focused on the use of fluorescence PDT optimiza-
tion in skin cancer. PDT provides lower risks and better cosmetic
results than surgery. However, there are variations in clinical PDT
outcome, partially due to limited utilization of quantitative imag-
ing tools. Utilizing PpIX fluorescence can allow PDT optimiza-
tion and improve its efficacy. In this respect, we implemented
the analysis of the wide-field fluorescence of PpIX, relating the
PpIX production and photodegradation with the PDT clinical
response. Our results indicate that the fluorescence monitoring
of PpIX production and photodegradation can be an indicative
of the PDT outcome in the treatment of BCC.
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